Timothy F. Cloughesy, MD

Timothy Cloughesy, MD, is the director of the neuro-oncology program at the UCLA Brain Research Institute.

Articles by Timothy F. Cloughesy, MD

Understanding Vorasidenib’s Mechanism of Action

August 13th 2024

Timothy F. Cloughesy, MD, director of UCLA’s neuro-oncology program and distinguished professor in neurology, discusses the mechanism of action of vorasidenib.

Cloughesy’s Insights on the FDA Approval of Vorasidenib in IDH-Mutant Gliomas

ByTimothy F. Cloughesy, MD

August 6th 2024

Timothy F. Cloughesy, MD, discusses the impact and significance of the FDA’s approval of vorasidenib, a first-in-class option for the treatment of patients with IDH-mutant gliomas.

Timothy F. Cloughesy, MD

Articles by Timothy F. Cloughesy, MD

Understanding Vorasidenib’s Mechanism of Action

Cloughesy’s Insights on the FDA Approval of Vorasidenib in IDH-Mutant Gliomas

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update